Serum levels of endocan correlate with the presence and severity of pre-eclampsia

Clinical and Experimental Hypertension

Volumn 38, Issue 2, 2016, Pages 137-142

  Cakmak, Muzaffer ^a   Yilmaz, Hakki ^b   Baʇlar, Esra ^a   Darcin, Tahir ^c   Inan, Osman ^d   Aktas, Aynur ^e   Celik, Huseyin Tugrul ^a   Ozdemir, Ozhan ^f   Atalay, Cemal Reşat ^f   Akcay, Ali ^a  

^a TURGUT OZAL UNIVERSITY   (Turkey)

^b Ankara Oncol Training/Res Hospital   (Turkey)

^c Agri Public Hospital   (Turkey)

^d Yenimahelle Training and Research Hospital ^*  (Turkey)

^e ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^f Ankara Numune Research and Educational Hospital   (Turkey)

Author keywords

biomarker; Endocan; pre eclampsia; pregnancy; proteinuria

Indexed keywords

BIOLOGICAL MARKER; DERMATAN SULFATE; ENDOCAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ESM1 PROTEIN, HUMAN; PROTEOGLYCAN; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; TUMOR PROTEIN;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; PREECLAMPSIA; PROTEIN BLOOD LEVEL; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; PREGNANCY; SEVERITY OF ILLNESS INDEX; URINE; YOUNG ADULT;

ADULT; BIOMARKERS; BLOOD PRESSURE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; NEOPLASM PROTEINS; PRE-ECLAMPSIA; PREGNANCY; PROTEINURIA; PROTEOGLYCANS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84959569627     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2015.1060993     Document Type: Article

References (32)

1. Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens 2008; 21: 521-6
2. Clark SL, Belfort MA, Dildy GA, et al. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol 2008; 199: 36.e1-5
3. Scantlebury DC, Hayes SN. How does preeclampsia predispose to future cardiovascular disease? Curr Hypertens Rep 2014; 16: 472
4. Al-Jameil N, Aziz Khan F, Fareed Khan M, Tabassum H. A brief overview of preeclampsia. J Clin Med Res 2014; 6: 1-7
5. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010; 376: 631-44
6. Bilodeau JF. Review: maternal and placental antioxidant response to preeclampsia-impact on vasoactive eicosanoids. Placenta 2014; 35: S32-8
7. Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 2014; 10: 466-80
8. Ferris TF. Pregnancy, preeclampsia, and the endothelial cell. N Engl J Med 1991; 325: 1439-40
9. Mustafa R, Ahmed S, Gupta A, Venuto RC. A comprehensive review of hypertension in pregnancy. J Pregnancy 2012; 2012: 105918
10. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996; 271: 20458-64
11. Ziol M, Sutton A, Calderaro J, et al. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. J Hepatol 2013; 59: 1264-70
12. Grigoriu BD, Depontieu F, Scherpereel A, et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 2006; 12: 4575-82
13. El Behery MM, Seksaka MA, Ibrahiem MA, et al. Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer. Arch Gynecol Obstet 2013; 288: 1371-6
14. Balta S, Mikhailidis DP, Demirkol S, et al. Endocan-a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology 2014; 65: 773-7
15. Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol 2013; 169: 1066-70
16. Yilmaz MI, Siriopol D, Saglam M, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 2014; 86: 1213-20
17. Kose M, Emet S, Akpinar TS, et al. Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology 2014; 66: 727-31
18. Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy Off J Int Soc Study Hypertens Pregnancy 2001; 20: IX-XIV
19. ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 77: 67-75
20. Levey AS, Stevens LA, Schmid CH, et al., CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12
21. Sánchez-Aranguren LC, Prada CE, Riaño-Medina CE, Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol 2014; 5: 372
22. Brennan LJ, Morton JS, Davidge ST. Vascular dysfunction in preeclampsia. Microcirculation 2014; 21: 4-14
23. Baker PN, Davidge ST, Barankiewicz J, Roberts JM. Plasma of preeclamptic women stimulates and then inhibits endothelial prostacyclin. Hypertension 1996; 27: 56-61
24. Khan F, Belch JJ, MacLeod M, Mires G. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension 2005; 46: 1123-8
25. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308: 1592-4
26. Szarka A, Rigó J Jr, Lázár L, et al. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010; 11: 59
27. Kupferminc MJ, Peaceman AM, Wigton TR, et al. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol 1994; 170: 1752-9
28. Serin IS, Ozcelik B, Basbug M, et al. Predictive value of tumor necrosis alpha (TNF-alpha) in preeclampsia. Eur J Obstet Gynecol Reprod Biol 2002; 100: 143-5
29. Adekola H, Romero R, Chaemsaithong P, et al. Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes. J Matern Fetal Neonatal Med 2014; DOI: 10.3109/14767058.2014.964676
30. Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol 2007; 18: 2281-4
31. Craici IM, Wagner SJ, Weissgerber TL, et al. Advances in the pathophysiology of pre-eclampsia and related podocyte injury. Kidney Int 2014; 86: 275-85
32. Zhang SM, Zuo L, Zhou Q, et al. Expression and distribution of endocan in human tissues. Biotech Histochem 2012; 87: 172-8